 Fluorouracil recombinant human interferon treatment metastatic chemotherapy-refractory urothelial tumors Thirty patients advanced metastatic chemotherapy-refractory urothelial tumors combination fluorouracil recombinant human interferon sites metastases present study patients median Eastern Cooperative Oncology Group performance status range patients primary methotrexate/cisplatin-based chemotherapy Nine confidence interval patients partial response mean duration response months median months range months patients partial response months duration control residual disease radiation surgical excision disease-free additional period months data combination recombinant human interferon synergistic clinical significance treatment urothelial tumors response rate combination drugs agents Additional confirmatory trials significance findings